ReviewFrontiers in immunology2025
Systemic lupus erythematosus complicated by severe Guillain-Barré syndrome: case report and literature review.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Guillain-Barré Syndrome as an Initial Manifestation of Systemic Lupus Erythematous: Rare Case Report.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous chronic autoimmune disease characterized by immune-mediated multiple organ injuries in the setting of autoimmunity to nuclear antigens. In rare cases, it can complicated by the damage of peripheral nervous system, manifesting as Guillain-Barré syndrome (GBS). Severe GBS as the initial presentation is highly infrequent and associated with high disability and mortality rates, highlighting the importance of early detection, diagnosis, and treatment. Herein, we reported a successfully treated case of severe SLE-GBS in a 38-year-old male. Furthermore, we summarize the clinical characteristics of severe SLE-GBS reported thus far and propose the possibility of using medium-to-high dose corticosteroids in the acute progression stage of SLE-GBS. This report provides valuable insights for the analysis of disease characteristics and guidance for diagnosis and treatment of such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.